Latest Ratios: P/E Ratio -3.2x · EV/EBITDA N/A · ROE -16.5%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $27M | $32M | $59M | $108M | $66M | $161M | $82M | $51M | $21M | $62M | $61M |
| Enterprise Value | $8M | $12M | $59M | $89M | $69M | $100M | $9M | $24M | $25M | $65M | $39M |
| P/E Ratio → | -3.21 | — | — | 1.60 | — | — | — | — | — | — | — |
| P/S Ratio | 1.33 | 1.53 | 15.67 | 0.77 | 13.06 | 12.23 | — | 421.77 | 82.30 | 241.45 | 236.27 |
| P/B Ratio | 0.55 | 0.64 | 1.07 | 1.48 | 20.56 | 3.90 | 3.60 | 3.96 | 0.68 | 2.90 | 1.74 |
| P/FCF | — | — | — | 1.79 | — | — | — | — | — | — | — |
| P/OCF | — | — | — | 1.79 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.61 | 15.73 | 0.63 | 13.60 | 7.60 | — | 198.33 | 96.48 | 253.83 | 152.99 |
| EV / EBITDA | — | — | — | 1.21 | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | 1.27 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | 1.48 | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 88.9% | 87.7% | 97.6% | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -78.0% | -78.0% | -990.8% | 51.9% | -1684.5% | -462.2% | — | -40430.6% | -11666.5% | -10241.2% | -10823.7% |
| Net Profit Margin | -41.8% | -41.8% | -568.3% | 47.8% | -1233.7% | -249.7% | — | -44388.4% | -4851.4% | -9751.0% | -11668.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.5% | -16.5% | -33.3% | 176.0% | -282.3% | -102.7% | -309.6% | -243.5% | -47.4% | -89.1% | -78.1% |
| ROA | -11.5% | -11.5% | -19.4% | 62.0% | -60.5% | -29.6% | -69.1% | -97.4% | -25.2% | -47.4% | -55.0% |
| ROIC | -28.2% | -28.2% | -50.9% | 181.6% | -1069.1% | — | — | -354.0% | -75.6% | -103.9% | -498.0% |
| ROCE | -26.8% | -26.8% | -41.6% | 79.7% | -97.2% | -66.7% | -83.7% | -104.7% | -72.2% | -57.4% | -56.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.30 | 0.21 | 15.03 | 1.06 | 0.87 | 1.15 | 0.48 | 0.68 | 0.41 |
| Debt / EBITDA | — | — | — | 0.21 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.39 | 0.00 | -0.26 | 0.86 | -1.48 | -3.22 | -2.10 | 0.12 | 0.15 | -0.61 |
| Net Debt / EBITDA | — | — | — | -0.26 | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | -0.32 | — | — | — | — | — | — | — |
| Interest Coverage | -48.76 | -48.76 | -7.95 | 11.48 | -8.95 | -8.40 | -47.38 | -23.90 | -8.35 | -12.51 | -65.49 |
Net cash position: cash ($21M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.04 | 7.04 | 3.00 | 6.26 | 4.49 | 8.03 | 3.72 | 4.76 | 8.76 | 4.43 | 15.96 |
| Quick Ratio | 7.04 | 7.04 | 3.00 | 6.26 | 4.44 | 8.00 | 3.72 | 4.76 | 8.67 | 4.36 | 15.84 |
| Cash Ratio | 3.71 | 3.71 | 2.46 | 4.56 | 4.17 | 7.67 | 3.52 | 4.40 | 7.51 | 4.33 | 15.76 |
| Asset Turnover | — | 0.35 | 0.04 | 1.09 | 0.06 | 0.11 | — | 0.00 | 0.00 | 0.01 | 0.00 |
| Inventory Turnover | — | — | — | — | 0.70 | 0.67 | — | — | — | — | — |
| Days Sales Outstanding | — | — | 999.90 | 56.85 | 150.63 | 23.87 | — | — | 9561.01 | 356.48 | 330.91 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 62.3% | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | 55.7% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $6M | $6M | $5M | $3M | $1M | $701017 | $548550 | $334329 | $237941 |
Binary regulatory manufacturing failure
As reported in financial statements, SCYX trades at a P/S multiple of 1.18, which appears to reflect deep market skepticism regarding the company's ability to transition from a milestone-dependent biotech entity to a sustainable, royalty-generating commercial enterprise following recent manufacturing and regulatory setbacks.
The current P/B ratio of 0.49 suggests that the market is pricing the company well below its book value, indicating that investors assign little to no value to the intangible assets or future pipeline potential. This valuation level implies that the market views the current business model as fundamentally impaired rather than merely undergoing a temporary transition period.
Based on SCYX's reported figures, the ROIC has remained deeply negative, reaching -68.7% in 2026Q1, which highlights a persistent inability to generate returns on invested capital while the company continues to burn through its remaining cash reserves to fund ongoing R&D and regulatory compliance efforts.
The extreme volatility in ROIC, swinging from positive territory in 2025Q4 to significant negative levels, confirms that the company's capital allocation is currently driven by lumpy milestone recognition rather than operational efficiency. This trend suggests that the company is failing to compound value, as the cost of maintaining its clinical and manufacturing infrastructure consistently outweighs the returns generated from its licensing activities.
According to recent SEC filings, the company's asset turnover ratio has remained near zero, reflecting a lack of meaningful commercial product movement and suggesting that the current operational structure is not yet optimized for the efficient conversion of inventory into sustainable, recurring revenue streams.
The erratic nature of the Days Sales Outstanding (DSO) metric, which has fluctuated wildly, indicates significant friction in the revenue collection process and potential issues with customer or partner payment cycles. Investors should monitor these efficiency ratios closely, as they suggest that the company's internal processes are struggling to keep pace with the demands of a commercial-stage pharmaceutical business.
As indicated by the balance sheet, the current ratio of 3.94 in 2026Q1 provides a superficial appearance of liquidity, yet this figure is misleading given the company's high cash burn rate and the absence of consistent, recurring revenue to support ongoing operational requirements.
While the quick ratio remains identical to the current ratio, suggesting minimal inventory dependence, the rapid contraction of the asset base implies that the company's liquidity position is highly fragile. Any further delays in milestone payments or regulatory hurdles could quickly exhaust this buffer, necessitating further dilutive financing to maintain operations.
Based on the provided data, the Price-to-Sales ratio is the most commonly misapplied metric for SCYX, as it fails to account for the lumpy, non-recurring nature of milestone-driven revenue that frequently distorts the company's true commercial performance and long-term earning potential.
Analysts should instead focus on adjusted cash burn and the net present value of future royalty streams, which better capture the underlying value of the triterpenoid antifungal platform. Relying on P/S multiples in this context obscures the reality that the company is currently a research-heavy entity rather than a mature commercial pharmaceutical firm.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SCYX stock.
SCYNEXIS, Inc.'s current P/E ratio is -3.2x. The historical average is 1.6x.
SCYNEXIS, Inc.'s return on equity (ROE) is -16.5%. The historical average is -95.6%.
Based on historical data, SCYNEXIS, Inc. is trading at a P/E of -3.2x. Compare with industry peers and growth rates for a complete picture.
SCYNEXIS, Inc. has 100.0% gross margin and -78.0% operating margin.